Chad Hatfield, Pharm.D., M.H.A., BCPS, vice president and chief pharmacy officer of UC Davis Health, says pharmacists are embedded in “nearly all specialties," with more than 150 holding board ...

Meta-analysis of 13 RCTs (2002–2024; eight countries) found VR reduced pain (SMD −0.76) and anxiety (SMD −1.53), largely ...

In stage II–IIIA disease, adjuvant osimertinib reduced mortality risk by 47%, with 74% alive at eight years versus 58% with ...

Divergent stakeholder needs emerged, with physicians prioritizing PA reduction and access tools, while patients prioritize affordability education, coverage clarity, and ongoing adherence support.

Poh says treatment of follicular lymphoma is entering an exciting era in follicular lymphoma with multiple treatment options ...

Employers that decide to stop covering GLP-1s for weight loss are increasingly pairing that decision with support for the ...

The treatment landscape continues to evolve, Poh says, and move away from a one-size-fits-all approach toward more individualized treatment strategies. Oncologists consider efficacy and durability of ...

U.S. healthcare is grappling with myriad challenges: improving care and quality, managing costs, navigating new payment structures and so much more. Who is addressing these challenges and guiding ...

Patients with hidradenitis suppurativa show elevated levels of dozens of inflammatory proteins in their blood, and several of ...

Vance said that canceling subsidy payments for 750,000 enrollees would save the federal government $2.2 billion. He said the investigation of the other enrollees would involve checking to see if they ...

The FDA approved Dupixent (dupilumab) as a treatment for moderate-to-severe atopic dermatitis for adolescents in 2019, then for older children, ages 6 to 11, a year later, and, two years later, for ...

Cardiovascular disease (CVD) became the leading cause of death in Hispanic adults in the U.S. in 2022, ahead of cancer, and researchers have been taking a closer look into this population of roughly ...